A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) — Stella
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(35 sites)
United States
University of Alabama at Birmingham, Birmingham, Alabama
University of California, Irvine, Irvine, California
University of Colorado Anschutz Medical Campus, Aurora, Colorado
Colorado Blood Cancer Institute, Denver, Colorado
Yale-New Haven Hospital, New Haven, Connecticut
University of Kansas Medical Center, Kansas City, Kansas
Local Institution - 0039, New Orleans, Louisiana
Local Institution - 0005, Boston, Massachusetts
Washington University School of Medicine, St Louis, Missouri
Hackensack University Medical Center, Hackensack, New Jersey
Icahn School of Medicine at Mount Sinai, New York, New York
Neurological Institute of New York, New York, New York
University of Cincinnati Medical Center, Cincinnati, Ohio
Belgium
Antwerp University Hospital, Edegem, Antwerpen
UZ Gent, Ghent, Oost-Vlaanderen
France
Hopital Claude Huriez - CHU de Lille, Lille, Nord
Pitie Salpetriere University Hospital, Paris, Ville de Paris
Germany
Universitaetsklinikum Essen, Essen, North Rhine-Westphalia